Bruker Corporation (BRKR)
OvervaluedFundamental
33
मूल्य
$62.65
मार्केट कैप
$9.87B
भाग 1 · कंपनी का मूल्य कितना है
अवलोकन
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools; innovative nuclear magnetic resonance (NMR) and electron paramagnetic resonance (EPR) products; solutions for in-vivo processes and drug discovery; aftermarket solutions; solutions for lab automation and digitalization; mass spectrometry solution and test kits, DNA test strips, and fluorescence-based PCR technologies; genotype and fluorotype molecular diagnostics kits; and research, analytical, and process analysis instruments and solutions. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; services for transcriptional profiling and multiomic analysis; superconducting materials, such as metallic low temperature superconductors; multifilament round and rectangular LTS wires in both monolithic and wire-in-channel formats; designs and manufactures Cuponal; metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation was founded in 1960 and is headquartered in Billerica, Massachusetts.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 18 सितंबर 2026 with claude-haiku-4-5 — shared with all users
Named by Bruker in its own 10-K, Thermo Fisher sells mass spectrometers, molecular spectroscopy and electron microscopy systems to the same pharmaceutical, academic and industrial laboratories Bruker serves worldwide.
Agilent competes head-on in mass spectrometry, chromatography coupling and molecular spectroscopy for life-science and applied-chemistry labs, the core of Bruker's CALID business.
Waters sells LC-MS platforms to the same pharmaceutical QC, proteomics and food-safety customers that buy Bruker's timsTOF and triple-quadrupole instruments.
Through SCIEX and Leica Microsystems, Danaher bids against Bruker for the same mass-spectrometry and high-end microscopy budgets in research and clinical laboratories.
Shimadzu offers a full analytical-instrument catalogue — mass spectrometry, spectrophotometry, surface analysis — and is Bruker's main Japanese rival in Asian academic and industrial accounts.
JEOL is the main alternative supplier of NMR and electron-microscopy systems, the market where Bruker's BioSpin division holds its strongest position.
बैलेंस शीट और तरलता
राजस्व
$3.50B
पिछले 12 महीने (30/6/2026 तक)
शुद्ध आय
$-71M
पिछले 12 महीने (30/6/2026 तक)
Free Cash Flow
$43M
कुल इक्विटी
$2.46B
कुल देनदारियाँ
$3.73B
Current Ratio
1.85
Interest Coverage
0.50
Debt/EBITDA
6.33
Earnings Per Share
राजस्व और शुद्ध आय
Free Cash Flow
आय विवरण
ऐतिहासिक विवरण
समय के साथ मार्जिन
समय के साथ ऋण
ऋण कितना भारी है
वृद्धि तालिका
वृद्धि — राजस्व
Fair Value अनुमान
Fair Value
$46.11
वर्तमान मूल्य
$62.65
Margin of Safety
-35.9%
Fair Value सीमा
$29.97 - $62.25
इस्तेमाल किए गए valuation methods के बीच का फैलाव, कोई सांख्यिकीय रूप से calibrated confidence interval नहीं।
अनुमान विधियाँ
मूल्यांकन मेट्रिक्स
P/E Ratio
-
ROE
-0.4%
P/B Ratio
4.11
P/FCF
105.06
Gross Margin
46.4%
ROIC
-0.5%
लाभप्रदता Radar
मूल्य सृजन (प्रतिस्पर्धी बढ़त)
ROIC
-0.5%
WACC
10.0%
ROIC − WACC
-10.5 pp
ROIC पूंजी की लागत से कम है — कंपनी निवेशित हर डॉलर पर मूल्य नष्ट कर रही है।
Fundamental विश्लेषण मानदंड
पास (10)
- Price CAGR 10.91%
- Gross Margin 46.4%
- Debt/Equity ratio
- Positive Free Cash Flow
- Current Ratio
- Revenue Growth 5Y 11.6%
- Analyst Consensus 62% Buy
- Earnings Surprise avg 19.0%
- Share Dilution -61.5%
- Piotroski F-Score 5/9
फेल (13)
- EPS shows upward trend
- ROIC -0.5%
- P/FCF 105.06
- P/B Ratio 4.11
- Operating Margin -0.9%
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- DCF valuation (Overvalued)
- ROE -2.9%
- Net Margin Trend -2.0% vs 2.3%
अनुपलब्ध (4)
- Dividend Payout NaN%
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
मिश्रित संकेत: कुछ क्षेत्रों पर ध्यान देना आवश्यक
Earnings गुणवत्ता
निम्न गुणवत्ता: accounting की जांच करें
शेयर Dilution
शेयर वापस खरीद रही है। शेयरधारक अनुकूल
संस्थागत होल्डिंग
प्रशासन
कार्यकारी टीम
| नाम | पद | आयु |
|---|---|---|
| Dr. Frank H. Laukien Ph.D. | Chairman, CEO & President | 65 |
| Mr. Gerald N. Herman CPA | Executive VP & CFO | 67 |
| Dr. Mark R. Munch Ph.D. | Corporate Executive VP and President of Bruker Nano Group & Corporate | 63 |
| Mr. Juergen W. Srega | President of Bruker Biosystems Group & Bruker Daltonics Division | 70 |
| Mr. Thomas M. Bures | Chief Accounting Officer | 50 |
| Mr. J. Brent Alldredge J.D. | Senior VP, General Counsel, Secretary & Global Head of Compliance | 50 |
| Dr. Wolfgang Pusch Ph.D. | President of Bruker Microbiology & Infection Diagnostics Group | - |
| Dr. Burkhard Prause Ph.D. | President and CEO of Bruker Energy & Supercon Technologies, Inc. | 58 |
Audit जोखिम
7
बोर्ड जोखिम
6
मुआवजा जोखिम
6
शेयरधारक अधिकार जोखिम
5
भाग 2 · कीमत और खरीदने का समय
यह हिस्सा यह नहीं बताता कि कंपनी अच्छी है या नहीं: यह तय करने में मदद करता है कि उसे कब खरीदें, जब फंडामेंटल आपको आश्वस्त कर चुके हों। इसमें: तकनीकी विश्लेषण, संभावना, ऐतिहासिक गिरावट, गामा एक्सपोज़र।
दस्तावेज़
- दस्तावेज़ देखें
वार्षिक रिपोर्ट (10-K)
कंपनी के कारोबार, वित्तीय नतीजों और जोखिमों का वार्षिक सिंहावलोकन।
दाखिल तिथि: 2026-02-27
- दस्तावेज़ देखें
तिमाही रिपोर्ट (10-Q)
पिछले तीन महीनों के वित्तीय प्रदर्शन का अपडेट।
दाखिल तिथि: 2026-08-05
- दस्तावेज़ देखें
विशेष रिपोर्ट (8-K)
किसी बड़ी घटना, जैसे नेतृत्व में बदलाव या बड़ी घोषणा, की सूचना।
दाखिल तिथि: 2026-08-14
via SEC EDGAR
आय का इतिहास
via SEC EDGAR
Latest News
Recent headlines for BRKR, sourced from Markets Gazette.